BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
BenzingaBenzinga Korea 한국
일요일, 9월 20

BioMarin Pharmaceutical Inc

BMRNNASDAQ
Trade with Public
Trade with Public
$63.94
-1.14-1.75%
가까이에: Sep 18, 5:00 PM EST
$63.94
-0.00250%
시간외: Sep 18, 4:28 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

BioMarin Pharmaceutical Financials

BioMarin Pharmaceutical (BMRN) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
BioMarin Pharmaceutical Raises FY2026 Adj EPS Guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 Est; Raises FY2026 Sales Guidance from $3.825B-$3.925B to $3.875B-$3.925B vs $3.875B Est

BioMarin Pharmaceutical (NASDAQ:BMRN) raises FY2026 Adj EPS guidance from $4.85-$5.05 to $4.90-$5.10 vs $3.64 analyst estimate. Raises FY2026 sales outlook from $3.825 billion-$3.925 billion to $3.875 billion-$3.925
Benzinga Newsdesk

PRO
Biomarin Pharmaceutical Q2 Adj. EPS $1.20 Beats $0.69 Estimate, Sales $990.000M Beat $926.908M Estimate

Biomarin Pharmaceutical (NASDAQ:BMRN) reported quarterly earnings of $1.20 per share which beat the analyst consensus estimate of $0.69 by 73.91 percent. This is a 16.67 percent decrease over earnings of $1.44 per share
Benzinga Newsdesk

PRO
BioMarin Pharmaceutical Lowers FY2026 Adj EPS Guidance from $4.95-$5.15 to $4.85-$5.05 vs $4.43 Est; Raises FY2026 Sales Guidance from $3.325B-$3.425B to $3.825B-$3.925B vs $3.635B Est

Benzinga Newsdesk

PRO
Biomarin Pharmaceutical Q1 Adj. EPS $0.76 Misses $0.79 Estimate, Sales $766.208M Beat $755.610M Estimate

Benzinga Newsdesk

Earnings Scheduled For May 4, 2026

Benzinga Insights

PRO
BioMarin Pharmaceutical Sees FY2026 Sales $3.325B-$3.425B vs $3.507B Est

BioMarin Pharmaceutical (NASDAQ:BMRN) sees FY2026 sales of $3.325 billion-$3.425 billion vs $3.507 billion analyst estimate.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

BenzingaBenzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved